Nurix Therapeutics, Inc. NRIX Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Nurix Therapeutics, Inc. (NRIX) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $0 in Q4 2025.
- How has Nurix Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Nurix Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss decreased by 100.0% year-over-year, from $8K to $0.